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Abstract
Background: Independent lines of evidence suggested that a large fraction of human genes
possess multiple promoters driving gene expression from distinct transcription start sites.
Understanding which promoter is employed in which cellular context is required to unravel gene
regulatory networks within the cell.
Results: We have developed a custom microarray platform that tiles roughly 35,000 alternative
putative promoters from nearly 7,000 genes in the human genome. To demonstrate the utility of
this array platform, we have analyzed the patterns of promoter usage in 17β-estradiol (E2)-treated
and untreated MCF7 cells and show widespread usage of alternative promoters. Most intriguingly,
we show that the downstream promoter in E2-sensitive multiple promoter genes tends to be very
close to the 3'-terminus of the gene, suggesting exotic mechanisms of expression regulation in
these genes.
Conclusion: The usage of alternative promoters greatly multiplies the transcriptional complexity
available within the human genome. The fact that many of these promoters are incapable of driving
the synthesis of a meaningful protein-encoding transcript further complicates the story.
Background
The regulation of human gene expression is known to be
an extraordinarily complex process, including transcrip-
tion, mRNA processing, mRNA transport, mRNA stability,
mRNA translation, protein modification and protein sta-
bility. Nevertheless, the picture that has emerged over the
past two to three decades is one in which the process of
transcription itself is a highly regulated process [1], and
one could easily believe that the combinatorial interac-
tion of multiple transcription factors within the gene pro-
moter is sufficient to explain this complexity. However,
genes with more than one promoter have been known for
some time [2], and recent studies using independent lines
of evidence have suggested that a large proportion of the
human genome is transcribed from both strands [3] and
numerous human genes have more than one promoter
allowing gene transcription in different cellular condi-
tions [4-7]. As summarized in Figure 1A, alternative pro-
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moters can take many different forms, producing a wide
variety of transcripts and proteins from a single gene
locus. Moreover, the use of alternative transcription initi-
ation sites also affects the splicing pattern of downstream
exons, creating a variety of different transcripts and pro-
tein products [8]. It is needless to say that these various
promoters greatly increase the regulatory control that the
cell has over the expression of the gene.
Alternative promoters can take on several forms (A): Two promoters on a single exon (top); alternative first exons (middle); a  downstream promoter is located within the intron region of another isoform (bottom) Figure 1
Alternative promoters can take on several forms (A): Two promoters on a single exon (top); alternative first 
exons (middle); a downstream promoter is located within the intron region of another isoform (bottom). The 
median number of promoters per gene on our microarray is three (B). There are a significant number of single-promoter 
genes on the array, but these are invariably share a bidirectional promoter with multi-promoter genes.
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Alternative promoters are of particular interest because
their aberrant expression has been linked to a number of
diseases, particularly cancer. There are a number of exper-
imentally well-characterized multiple promoters for
known genes, for example TP53 [9], MYC [10], CYP19A1
[11], BRCA1 [12], P73 [13], MID1 [14], CTSB [15], SRC
[16], KLK6 [17] and TGFB3 [18], to name a few. CYP19A1
is a well-characterized example that has five known alter-
native promoters, many of which are separated by more
than 10 kb and are therefore regulated by completely non-
overlapping promoters [19]. Alternative first exons Ex-1.1,
Ex-1.3/Ex-1.4, and Ex-1f splice with Ex-2 to encode the 5'
prime untranslated regions (UTR) of CYP19A1 mRNA in
the placenta, adipose tissue, and brain, respectively. Addi-
tionally, in gonads, the transcription starts just 39 bp
upstream of translation initiation codon in exon-2. The
use of alternative non-coding first exons in the CYP19A1
transcripts does not alter the protein sequence, as the dif-
ferent 5'UTRs splice into a common second exon (exon-2)
that contains the translation initiation codon. It is known
that theses various promoters are used in a tissue-depend-
ent manner [19], but the promoter upstream of exon Ex-
1.4 is aberrantly expressed in breast cancer tissue, aggra-
vating the disease [11].
Many putative gene promoters have been identified either
through mapping of expressed sequence tags (ESTs) to the
genome (Acembly [20], ECGene [21]), through sequence
conservation studies with other organisms [22] or de novo
computational prediction (e.g., FirstEF [23], DragonGSF
[24]). Databases such as MPromDb [25] and H-DBAS
[26] provide information about well-curated promoters
and alternative spliced transcripts identified by aligning
completely sequenced and precisely annotated full-length
cDNAs [4]. Recently, intensive efforts have been invested
in establishing genome-wide profiling methods to iden-
tify the regulatory regions, including alternative transcrip-
tion start sites and the upstream promoter regions in
human and mouse genomes [27]. Currently, three ways
were applied for this purpose. One is based on the
decreased nucleosome occupancy and increased sensitiv-
ity to DNase of the active promoter regions. The two
approaches, called DNase-chip and DNase-array, have
been created to detect those transcribed promoters and
transcripts [28,29]. The second one is called the cap anal-
ysis gene expression (CAGE), combining full-length
cDNA library with SAGE technology to screen those 5'
parts of transcripts [30]. The third one is using ChIP-chip
(Chromatin ImmunoPrecipitation followed by microar-
ray analysis) to profile the binding position of the RNA
polymerase II preinitiation complex [31]. The data from
these studies provide evidence of large-scale alternative
splicing and wide-spread use of alternative promoters
throughout the mammalian genomes. Most of these
methods cannot predict the mRNA sequence produced
from that promoter, and therefore constructing a tradi-
tional cDNA microarray to detect their expression is
impossible. Moreover, two promoters may produce
mRNA isoforms that are nearly indistinguishable, again
making expression microarrays difficult to design. One
alternative is to use ChIP-chip to detect the binding of
RNA polymerase II to the genome. Although there is evi-
dence that the presence of RNA polymerase II in the pro-
moter does not perfectly correlate with active
transcription [32], there does exist a correlation between
the two events and therefore RNA polymerase II binding
is a good approximation of transcriptional activity
[33,34]. Here, we have taken an intermediate approach,
where we first annotated all possible putative promoters
in the human genome by integrative bioinformatics anal-
yses. Using these annotations, we designed 60-mer probes
complementary to sequences and tiling the core promoter
regions (both known and putative) of a subset of genes
that have at least two annotated promoters. We tested this
array by conducting ChIP-chip using antibody against
RNA polymerase II (RNA Pol II) in MCF7 cells without
and with E2 treatment. It is well known that estrogen
receptor can act both as an activator and repressor of spe-
cific target genes, and that these events can then affect cell
division and breast cancer progression [35,36]. Knowl-
edge about which of the alternative promoters of the ER
regulated genes are active and inactive in E2 treated and
untreated conditions in MCF7 cells would lead to better
understanding of their effects in breast cancer develop-
ment. Several novel putative promoters were found to be
active before and after E2 treatment. Interestingly, we
found that in genes with more than one putative pro-
moter, downstream promoters are much more likely to be
affected by E2 treatment than upstream promoters, sug-
gesting interesting mechanisms of gene regulation in mul-
tiple promoter genes.
Results
Alternative promoter array
In order to design an alternative promoter array, we first
used a bioinformatics approach to annotate all known
and putative promoters in the human genome. Using evi-
dence from three sources: UCSC Known Genes [37],
FirstEF [23], and Riken CAGE tags [38], we found evi-
dence for more than 185,000 transcription start sites sep-
arated by 500 bases or more in the human genome. We
took a gene-centric approach to our microarray design,
choosing genes that had two or more known or putative
promoters. In the end, about 34,000 known or putative
promoters were selected for our array, covering about
7,000 genes. The median number of promoters per gene
is three (Figure 1B). 60 mer oligonucleotide probes were
designed to tile a region -200 to +200 surrounding each
known and putative transcription start site. Because of
limitations on probe design, not all regions could be effec-BMC Genomics 2008, 9:349 http://www.biomedcentral.com/1471-2164/9/349
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tively covered but on average the spacing is approximately
80 bases from the end of one probe to the beginning of
the next.
Genome-wide profile of potential promoter usage
In order to identify potential active promoters, we con-
ducted ChIP-chip with antibody against RNA Pol II in
MCF-7 cell lines with and without E2 treatment for 3
hours, as described in the Methods. The amplified immu-
noprecipitated DNA and input control, after labeling with
Cy5 and Cy3 fluorescent dyes respectively, was used to
probe the alternative promoter microarray (Figure 2A).
Each experiment was repeated once to determine the
reproducibility of the probe hybridization intensities.
After filtering the low quality spots, we performed inten-
sity dependent Lowess normalization. The MA plot for
normalized data is shown in Figure 2B for one control
(before E2 treatment) experiment. We, then, plotted the
distribution of the normalized log ratios of red and green
intensities. The histogram in Figure 2C presents the log
ratios for one control experiment, which shows a clear bi-
modal distribution. The distribution with mode close to
zero represents the probes that are non-responsive and the
distribution with mode close to 2.5 represents the probes
of responsive promoters. The Expectation Maximization
(EM) algorithm of Khalili et al [39] was modified from the
original Gamma-Normal-Gamma fit to a simple Gamma-
Normal fit that appeared to be more appropriate for our
ChIP-chip procedure (A). MA plot for a control experiment, after normalization (B; M = log2(Red/Green); A =  log2(Red*Green)/2) Figure 2
ChIP-chip procedure (A). MA plot for a control experiment, after normalization (B; M = log2(Red/Green); A = 
log2(Red*Green)/2). Fit of the gamma+normal model to the log ratio of red versus green channels (C). The red portion of 
the histogram shows probes that belong to the unbound distribution with p < 0.05. The green portion of the histogram are 
probes that belong to the bound distribution with p < 0.05. The grey areas in between are ambiguous. Our model allows us to 
annotate promoters as being active or inactive at different confidence levels (D). "High on" indicates strong evidence for RNA 
Polymerase II binding in both replicates (the probes fall within the green portion of panel C); "Medium on" indicates strong evi-
dence for RNA Polymerase II binding in one replicate, and weak evidence in the other (i.e., the probes fall outside of the red 
area in panel C). "Low on" indicates weak evidence in both replicates. "Low off" indicates inconsistency between the replicates, 
and finally "Strong off" indicates a high probability that no binding occurred (i.e., probes fall within the red portion of panel C). 
"Low on" indicates weak evidence in both replicates. "Low off" indicates inconsistency between the replicates, and finally 
"Strong off" indicates a high probability that no binding occurred (i.e., probes fall within the red portion of panel C).
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data. The algorithm clearly defines two distinct distribu-
tions in Figure 2C, representing the unbound probes (in
red) and the bound probes (in green). See Additional File
1 for the MA plots and log ratio distribution of data from
other experiments. A nice feature of the algorithm is that
probes can be assigned to each distribution with a certain
probability, allowing us to increase or reduce the strin-
gency of our assignments easily. We defined strong candi-
dates for RNA Polymerase II activity as those probes that
fell within the green distribution with a p-value of at most
0.05. However, we also defined a second, weaker condi-
tion: those probes that are not significantly part of the
larger unbound (red) distribution at a p-value of 0.05.
This latter group would encompass the "grey area" that
lies between the two distributions. The "best" probe from
each promoter was used to evaluate the activity of the pro-
moter as a whole. Figure 2D shows the proportion of
active promoters in MCF7 cells at different quality thresh-
olds. At least 65% of the promoters (both putative and
known) are inactive in this cell line, whereas ~17% of the
promoters have strong evidence for being active. This is
roughly in accordance with previous genome-wide studies
of promoter activity. For example, Kim et al [31] found
~9,300 active promoters in IMR90 cells, which corre-
sponds to ~23% of the unique annotated transcription
start sites in the UCSC known genes [37]. When we map
these promoters back to genes, we find that 3,210 genes
had at least one promoter active in at least on experimen-
tal condition, out of a total 6,500 genes for which we were
able to recover data – roughly 50%.
We validated a total of 18 promoters, 10 promoters that
we predicted to be active with high confidence and 8 pro-
moters that were predicted to be inactive in MCF7 cells.
ChIP-PCR experiments showed that these predictions
were for the most part accurate (Figure 3) – seven out of
the ten positive targets microarray analysis were con-
firmed to be bound to RNA polymerase II. Similarly, all
but one of the negative samples showed no evidence of
RNA polymerase II binding. Although the binding of RNA
polymerase II to the promoter region needn't correlate to
gene expression because of posttranscriptional events, we
find that a rough correspondence does exist. For example,
two promoters in the gene NCOA7 were shown to bind to
RNA polymerase II with a "low" level of confidence,
although in the absence of E2 the upstream promoter was
predicted to be "strongly off" (Figure 4A). These qualita-
tive results were verified by quantitative reverse tran-
scriptase-polymerase chain reaction (qRT-PCR) (Figures
4B and 4C). By comparing these results to the gene
EIF3S9, whose most upstream promoter was "highly on"
in both treatments (Figure 5A), we found that the qRT-
PCR experiments showed a correspondingly high level of
expression of the corresponding gene isoform (Figure 5B).
Alternative promoters and CpG islands
Wang et al. [40] recently noted that the 5'-most promoter
of a gene tends to be CpG related, while more down-
stream promoters are less likely to be. We identified pro-
moters that were active in one or both of our treatments,
and classified them as either being associated with the 5'-
end of the gene (if the promoter was located < 500 bases
of the 5' end of the gene's annotation) or downstream
promoters (> 500 bases away from the 5' end of the gene).
Similar to the findings of Wang et al., we found that 92%
of all 5'-end promoters are associated with a CpG island,
whereas only 23% of downstream promoters are.
Identification of novel promoters
As shown in Table 1, each promoter on the array is sup-
ported by different lines of evidence. The most common
promoters are those that are supported by multiple CAGE
tags. However, only 14% of the 18,902 such promoters
supported by only CAGE tags on the array were found to
be active at "high" or "medium" confidence levels. Of
course, it is important to note that a negative result does
not necessarily indicate an inaccurate promoter predic-
tion; these promoters may be active in different cell types,
or under different environmental conditions. Therefore,
these numbers should be seen as a lower limit. By far, the
greatest concordance was found for CpG-related promot-
ers that are supported by all lines of evidence (UCSC
Known Genes, CAGE tags, and FirstEF predictions), of
these 68% were found to be active. The data also indicate
that the CpG-related promoters that are supported by
both CAGE tags and FirstEF predictions enjoy a higher rate
of success than those promoters that are exclusively sup-
ported by either CAGE tags or FirstEF predictions. 16% of
non-CpG-related promoters in this category were found
to be active, while an impressive 39% of CpG-related pro-
moters supported by CAGE and FirstEF results were found
to be active. In all, if we consider all promoters not sup-
ported by KnownGenes to be "novel", then out of 20,879
promoters, 3,172 (15%) were active in at least one treat-
ment. If we eliminate promoters supported only by CAGE
tags, then 601 out of 1,977 promoters (30%) are found to
be active. Of the ten genes selected for validation in Figure
4, eight fall into the novel category (i.e., no mRNA evi-
dence) and six of these were confirmed (see Table 2).
These surprising results indicate that large numbers of
undiscovered, unannotated promoters exist within
human genes. Notably, we have discovered 303 new and
active promoters that are situated more than 500 bases
upstream of the currently-defined 5' end of the gene, sug-
gesting that a significant fraction of the current gene anno-
tations may not be 5'-complete. One of these promoters
was upstream of SOX12, and was verified to bind to RNA
polymerase II (Figure 4). These results also strongly sup-
port the recent reports of high frequency of alternative
promoter in mammalian genomes [41,42]. In addition,BMC Genomics 2008, 9:349 http://www.biomedcentral.com/1471-2164/9/349
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the complicated distribution patterns of these alternative
promoters might be easily overlooked by previous expres-
sion array analyses.
Differential use of multiple promoters with estrogen 
stimulation
Our hypothesis was that treatment with E2 affects the pro-
moter activity of a sub-set of genes in the genome. For this
analysis, we defined "active" as promoters with "high",
"medium" or "low" confidence. For the subset of genes
that have single active promoter, we found that 2,697 pro-
moters were active in both E2- and E2+ treated conditions
(see Additional File 2). Whereas only 178 promoters were
inactivated and 77 promoters were activated by E2. This
bias towards inactivation is highly significant (p = 2.5e-10
in a chi-squared test), indicating that more promoters are
inactivated by E2 than are activated, which supports the
previous report about estrogen-mediated early-down reg-
ulated genes [43]. Some of the genes associated with these
promoters have previously been identified as being estro-
gen sensitive, such as GREB1, HSPB8, and WFS1 [44] (see
Additional Files 2 and 3 for a complete list). We next con-
sidered those genes that have two active alternative pro-
moters and checked for the differential activation or
inactivation of the promoters. We found 993 genes with
both promoters active and not affected by E2 treatment
Seven out of ten promoters were confirmed to be active based on ChIP-PCR assays (green bars) Figure 3
Seven out of ten promoters were confirmed to be active based on ChIP-PCR assays (green bars). Similarly, all 
but one of the promoters called as negative showed no evidence for RNA polymerase II binding (red bars). Error bars indicate 
standard errors from the mean, based on three replicates.
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(see Additional File 3). More interesting are the cases
where one promoter is affected by E2 treatment. The
upstream promoters of 25 such genes are activated by E2
(Figure 6A; also see the gene NCOA7 in Figure 4), whereas
in 61 genes the upstream promoter is inactivated by E2
(Figure 6B) – a more than 2:1 bias in favor of inactivation,
which is quite similar to what we found in the single
active promoter gene case, and also significant (p =
0.000175 in a chi-squared test). Curiously, this same bias
is not present when we examined the downstream pro-
Shown here are the first four exons of the gene NCOA7, spanning a region of roughly 32 kb (A). Exon 3 is spliced out of the  transcript initiated at Exon 1, but Exon 4 is common to both transcripts Figure 4
Shown here are the first four exons of the gene NCOA7, spanning a region of roughly 32 kb (A). Exon 3 is spliced 
out of the transcript initiated at Exon 1, but Exon 4 is common to both transcripts. The ChIP-chip microarray analysis indicated 
that the first promoter is inactive in the control experiment, but is activated with E2 treatment at a low level, a result that is 
verified by qRT-PCR results (B). The second promoter was predicted to be active at a low level with and without E2 treat-
ment, which again was verified (C). Error bars indicate standard errors from the mean for three replicates.
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moters, where we found 62 were activated by E2 (Figure
6C) and 64 were inactivated by E2 (Figure 6D).
In terms of the overall differential usage (either activation
or inactivation) of alternative promoters due to E2 treat-
ment, we found that the downstream promoters are more
often affected by E2 treatment than the upstream pro-
moter. We found that there were a total of 127 down-
stream promoters affected by E2 treatment, while only 87
upstream promoters were affected – a significant bias (p =
0.00625 in a chi-squared test). These intriguing patterns
provide some insight into the regulatory control of genes
Shown here are the first three exons of the gene EIF3S9, spanning a region of approximately 3.7 kb (A). This promoter was  shown to be highly active in both treatments, which was verified by qRT-PCR Figure 5
Shown here are the first three exons of the gene EIF3S9, spanning a region of approximately 3.7 kb (A). This 
promoter was shown to be highly active in both treatments, which was verified by qRT-PCR. Error bars indicate standard 
errors from the mean for three replicates.
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and their isoforms by E2. To investigate this phenomenon
further, we examined the locations of active promoters
within each gene. As shown in Figure 7A, for genes with a
single active promoter that is insensitive to E2 treatment
there is a strong tendency for that promoter to be located
at the 5' end of the annotated gene. Similar trends are
observed in genes with two active promoters that are
insensitive to E2 treatment, where the upstream promoter
is again located near the 5' end of the gene, while the loca-
tion of the downstream promoter is uniformly distributed
throughout the length of the gene (Figure 7B). However,
a surprising change is observed if one of the promoters is
E2-sensitive, where we found that there was a very strong
tendency for the downstream promoter to be close to the
3' end of the gene (Figure 7C). In keeping with our finding
that downstream promoters tend to not be associated
with CpG islands (in contrast with promoters at the 5'-
end of the gene), E2-sensitive promoters are overall less
likely to be associated with CpG islands than active pro-
moters taken as a whole: 50% of all active promoters are
CpG-related, while only 37% of E2-sensitive promoters
are (p = 1.2e-11 in a Fisher's Exact test).
Discussion
Although genome tiling arrays are increasingly becoming
a viable alternative to focused microarrays, they remain
significantly more expensive than focused microarrays,
and their signal-to-noise ratio is very high due to the large
numbers of inactive probes and lack of probe design con-
siderations [45]. Another alternative mechanism for stud-
ying alternative promoters is the use of traditional
expression arrays that have been designed to specifically
interrogate particular gene isoforms. Unfortunately, in a
large number of cases, mRNA isoforms are not known for
putative promoters, and many isoforms that originate at
different promoters differ only in the first exon – a small
percentage of the entire molecule, making it difficult to
distinguish between the various isoforms. High-through-
put sequencing techniques are a recent advance that pro-
vide an attractive alternative to microarray-based
techniques [33], however there is evidence that ChIP-chip
is more sensitive than ChIP-sequencing techniques [46].
Traditionally, expression analysis was used to define pro-
moter activity. However, one recent report has found that
a number of genes experience transcription initiation but
show not detectable full-length transcripts [32]. Neverthe-
less, additional reports indicate that a correlation does
exist between Pol II occupancy and gene activation
[33,34]. The findings of Guenther et al. may be explained
by post-transcriptional regulation, but in any case we
believe that the presence of Pol II in the promoter is a
good approximation of promoter activity, although fur-
ther experiments are still necessary to define and charac-
terize this relationship.
Here, we have presented a novel 244 k microarray that is
capable of measuring alternative promoter usage in over
34,000 putative promoters from nearly 7,000 genes. This
platform is suitable for indirect expression analyses using
Table 1: Activity of promoters with various combinations of supporting evidence
Evidence CpG-related Number of promoters Number of active promoters Percentage
KnownGene Yes 28 2 7.10%
No 792 84 10.60%
CAGE Yes 616 38 6.20%
No 18286 2533 13.90%
FirstEF Yes 129 26 20.20%
No 184 48 26.10%
KnownGene, CAGE Yes 93 9 9.70%
No 910 81 8.90%
KnownGene, FirstEF Yes 63 25 39.70%
No 45 10 22.20%
CAGE, FirstEF Yes 1123 440 39.20%
No 541 87 16.10%
KnownGene, CAGE, FirstEF Yes 3202 2170 67.80%
No 154 60 39.00%
Table 2: Promoters validated by ChIP-PCR and the lines of 
evidence used to identify them
Gene Symbol Genomic location (hg18) Evidence
ACPT chr19:55989804-55990068 CAGE tags
PPP2R2A chr8:25959258-25959687 FirstEF
ZNF85 chr19:20897730-20898104 KnownGene
APEG1 chr2:220021650-220021924 FirstEF + CAGE tags
KCNK3 chr2:26804455-26804795 FirstEF + CAGE tags
PPFIA3 chr19:54322857-54323287 FirstEF + CAGE tags
SHRM chr4:77829597-77830023 FirstEF + CAGE tags
SOX12 chr20:253659-254066 FirstEF + CAGE tagsBMC Genomics 2008, 9:349 http://www.biomedcentral.com/1471-2164/9/349
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RNA polymerase II ChIP-chip as we have shown in this
paper, but it is also suitable for methylation based studies
using DMH or meDIP experiments (since more than 5000
of the putative promoters fall within CpG islands), or for
ChIP-chip experiments using other proteins of interest,
such as transcription factors or histone modification sig-
natures. We have demonstrated clear evidence for alterna-
tive promoter activities within genes, including the
verification of a number of putative promoters. These
results suggest that a large fraction of genes in the human
genome possess undiscovered promoters and transcrip-
tion start sites, which agrees with findings based on the
mapping of ESTs to the genome [20,21], and the mapping
of 5' oligo cap cDNA libraries to the genome [4].
Most intriguingly, we discovered that there is a distinct
bias for the downstream promoter in E2-sensitive two-
promoter genes to be very close to the 3' end of the gene,
whereas no such bias exists in E2-insensitive genes. These
promoters are very unlikely to produce a functional tran-
script of any sort, and we therefore speculate that its pur-
pose is merely to regulate the expression of the transcript
initiated at the upstream promoter by "blocking" the pro-
gression of the RNA polymerase II complex. This "stall-
ing" mechanism has been observed in other contexts. For
example, inhibiting DNA replication was recently found
to cause RNA polymerase II to stall during the transcrip-
tion of p21 [47]. Similarly, the cofactor of BRCA1
(COBRA1) is known to cause stalling of the RNA polymer-
ase II complex proximal to the promoter [48,49]. How-
ever, we can think of no reason for "blocking" promoters
to have a bias towards the 3' end of the gene, since this
blocking action could be realized at any point relative to
the primary promoter. An alternative possibility is that
We found a total of 212 genes that had exactly two promoters that were active in one of these experiments Figure 6
We found a total of 212 genes that had exactly two promoters that were active in one of these experiments. 
Of these, the upstream promoter was activated by E2 in 25 genes (A), and was inactivated by E2 in 61 cases (B). The down-
stream promoter was activated by E2 treatment in 62 cases (C), and inactivated by E2 in 64 cases (D).
25
A
E2+
E2- 62
C
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E2-
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B
E2+
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D
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promoters near the 3' end of the gene are driving expres-
sion of an interfering RNA, either antisense to the primary
transcript or that is capable of inhibiting the formation
and progression of the RNA polymerase II complex at the
primary promoter [50]. Such noncoding, interfering RNAs
are known to regulate expression of the DHFR gene in
humans, for example, although in this case the interfering
RNA is transcribed from a promoter that lies upstream of
the primary promoter [51,52]. Much more work will need
to be performed in the future to identify the regulatory
action that these 3'-UTR promoters have on their primary
transcripts, if any.
Conclusion
We have demonstrated clear evidence of alternative pro-
moter activity for approximately 7,000 human genes,
using a 244 K custom microarray that span across 34,000
putative promoters. Our results suggest that a large frac-
tion of genes in the human genome possess undiscovered
alternative promoters, which agrees with findings based
on the mapping of ESTs and CAGE tags to the human
genome. We found that a significantly more number of
downstream promoters were affected by E2 treatment
than the upstream promoters. And, there is a distinct bias
for the downstream promoter in E2-sensitive two-pro-
moter genes to be very close to the 3' end of the gene,
whereas no such bias exists in E2-insensitive genes. The
custom microarray can also be used for epigenome analy-
ses, such as methylation based studies using DMH or
meDIP experiments. The present data will help discovery
of novel promoters and ongoing annotation of alternative
promoters of human genes in different experimental con-
ditions.
Methods
Microarray design
Target identification
We considered three sources of evidence for identifying
promoter targets for our microarray. The first was the 5'-
end of genes as identified in the UCSC Known Gene track,
which is largely based on the alignment of RefSeq mRNAs
to the human genome [37]. A second line of evidence was
the database of CAGE tags sequenced by the Riken group
[38]. These tags capture ~20 bases at the 5' end of messen-
ger RNAs, and have been mapped back to the human
genome. We used the UCSC LiftOver tool to convert
Riken's hg17 human genome coordinates to the more
recent hg18 genome. Our final line of evidence was ab ini-
tio promoter predictions generated by the FirstEF program
[23].
Each line of evidence identifies a transcription start site
(TSS). We considered TSSs separated by > 500 bp to be
distinct promoters – a commonly used criterion.
Although there are undoubtedly transcription factor bind-
For genes with a single active promoter, there is a strong  tendency for that promoter to be located at the 5' end of the  annotated gene, marked as "upstream", versus the 3'-end of  the gene which is marked as "downstream" (A). Similar  trends are observed in the case of genes with two active pro- moters where neither is affected by E2 treatment Figure 7
For genes with a single active promoter, there is a 
strong tendency for that promoter to be located at 
the 5' end of the annotated gene, marked as 
"upstream", versus the 3'-end of the gene which is 
marked as "downstream" (A). Similar trends are 
observed in the case of genes with two active promoters 
where neither is affected by E2 treatment. Here, one of the 
promoters is likely to be at the 5' end of the gene, while the 
other promoter can occur anywhere else along the gene 
length with roughly equal probability (B). A different pattern 
is observed in genes with two active promoters where one is 
affected by E2 treatment (either activated or inactivated). In 
this case we can see that, as before, the upstream active pro-
moter is likely to be located at the 5' end of the gene, but the 
downstream promoter is strongly biased towards the 3' end 
of the gene (C).
-50 0 50 100
0
2
0
0
6
0
0
1
0
0
0 A
-50 0 50 100
0
1
0
0
3
0
0
5
0
0
B
-50 0 50 100
0
1
0
2
0
3
0
4
0 C
N
u
m
b
e
r
 
o
f
 
g
e
n
e
s
Relative distance from 5' end of the gene (%)
C
N
u
m
b
e
r
 
o
f
 
g
e
n
e
s
Relative distance from 5' end of the gene (%)BMC Genomics 2008, 9:349 http://www.biomedcentral.com/1471-2164/9/349
Page 12 of 15
(page number not for citation purposes)
ing sites that extend beyond this region, this distance is
great enough for the core promoters of each TSS to be dis-
tinct [25], and we can therefore consider these TSSs to be
independently regulated to a large extent. TSSs were clus-
tered using a neighbor-joining algorithm [53] until all
clusters were separated by at least 500 bases. The coordi-
nates of these clusters were then extended 200 bases up-
and downstream.
Probe selection
Each promoter region was aligned to the genome using
BLAT [54] in order to discover regions that are not unique.
Alignments that were longer than 55 bases (90% of the
probe length) were masked, as were 60 mers within the
sequence that had > 85% or < 50% G+C. From the
remaining unmasked regions of each promoter, probes
were selected such that the average spacing would be
roughly 100 bases, but that the spacing between two suc-
cessive probes would be no more than 300 bases. In the
end, the true average spacing is 80 bases.
Gene and promoter selection
Not all genes could be put on the array, so to prioritize we
assigned each gene a score. Three points were awarded for
each promoter supported by "known gene" evidence, two
points for those supported by CAGE tag evidence [38],
and one point for FirstEF [23] evidence. Genes were then
ranked by their total score, and only the best-scoring
genes were included on the array. In the end, the roughly
244,000 probes cover 34,486 promoter regions from
6,949 genes, with a median tiling coverage of 5 probes per
promoter. The median number of promoters per gene on
the array is 3, although the range is from 1 to over 30 (Fig-
ure 1B)
Cell culture
MCF-7 human breast cancer cells (American Type Culture
Collection, Manassas, VA) were maintained in growth
medium (MEM with 2 mM L-glutamine, 0.1 mM non-
essential amino acids, 50 units/ml penicillin, 50 μg/ml
streptomycin, 6 ng/ml insulin, and 10% FBS) as described
by Fan et al [55]. Prior to all experiments, cells were cul-
tured in hormone-free basal basal medium (phenol-red
free MEM with 2 mM L-glutamine, 0.1 mM non-essential
amino acids, 50 units/ml penicillin, 50 μg/ml streptomy-
cin, and 3% charcoal-dextran stripped FBS) for three days.
Chromatin immunoprecipitation on microarray (ChIP-
chip) assay
Five million MCF-7 cells with and without E2 treatment
(10 nM, 3 h) were crosslinked with 1% formaldehyde for
10 min, at which point 0.125 M glycine was used to stop
the cross-linking. Chromatin immunoprecipitation was
performed using a ChIP assay kit (Upstate Biotechnology,
Charlottesville, VA) as described [56]. The antibodies,
which specifically target against the initiation form of Pol
II, were purchased from Santa Cruz Biotechnology (sc-
899X, Santa Cruz, CA). Ligation-mediated PCR was
applied to 20 ng of ChIP DNA and input control as
described by Ren et al [57]. Briefly, after cross-linking,
cells were lysed and then sonication was used to shear the
chromatin to fragments of around 500 bp. Cell lysis was
then subject to immunoprecipitation. After immunopre-
cipitation, part of supernatant was removed from the lysis
as input control. The primers used in ligation-mediated
PCR were: oligo JW102, 5'-GCGGTGACCCGGGAGATCT-
GAATTC-3' and JW103 5'-GAATTCAGATC-3'. Tow μg of
amplified ChIP DNA and input control were then labeled
by Cy5 and Cy3 fluorescent dyes (Amersham, Bucking-
hamshire, UK) and were then cohybridized to the custom
alternative promoter array. Technical duplication was per-
formed for each sample of ChIP DNA. The slides were
washed with three wash buffers (Buffer I. 6× SSPE +
0.005% sarcosine; Buffer 2, 0.06× SSPE; Buffer 3, anti-oxi-
dant mixture in acetonitrile purchased from Agilent) in
series at room temperature.
Chromatin immunoprecipitation- quantitative polymerase 
chain reaction
ChIP was conducted in the same manner as in the ChIP-
chip experiments, described above. The pooled DNA from
ChIP and input control were first measured by spectro-
photometer (NanoDrop, Wilmington, DE). Quantitative
PCR with SYBR green-based detection (Applied Biosys-
tems, Foster City, CA) was performed as described previ-
ously. In brief, primers were designed using Primer
Express software (Applied Biosystems, Foster City, CA).
Quantitative ChIP-PCR values were normalized against
values from a standard curve (50 to 0.08 ng, R-squared >
0.99) constructed by input control with the same primer
sets.
Quantitative reverse transcription-polymerase chain 
reaction
Qiagen RNeasy kit (Valencia, CA) was used to extract total
RNA from MCF-7 cells with or without E2 treatment
according to the manufacture's manual. Two μg of RNA
was first treated with DNase I (Invitrogen, Carlsbad, CA)
to remove potential DNA contamination and then was
reverse transcribed with SuperScript II reverse tran-
scriptase (Invitrogen, Carlsbad, CA). Quantitative RT-PCR
was performed by using SYBR green (Applied Biosystems,
Foster City, CA) as a marker for DNA amplification on a
7500 Real-Time PCR System apparatus (Applied Biosys-
tems, Foster City, CA). The relative mRNA level of a given
locus was calculated by relative quantization of gene
expression (Applied Biosystems, Foster City, CA) with glu-
cose phosphate isomerase mRNA as an internal control.BMC Genomics 2008, 9:349 http://www.biomedcentral.com/1471-2164/9/349
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Microarray analysis
The washed slides were scanned by a GenePix 4000A scan-
ner (Axon, Union City, CA) and the acquired microarray
images were analyzed using GenePix 6.0 software. Briefly,
the user-selectable laser power settings for Cy5 (635 nm,
red) and Cy3 (532 nm, green) were adjusted so that the
overall Cy5 to Cy3 ratios were close to 1 and that the sig-
nal intensities spanned the entire spectrum with minimal
signal saturation at the high intensity range. When these
conditions were satisfied, the microarray was scanned and
a grid file was loaded to mark the general location of the
scanned image. The GenePix 6.0 software performed a
spot finding function and captured intensity-related infor-
mation in a GPR file.
The complete array dataset can be viewed in the ArrayEx-
press microarray database (accession number E-MEXP-
1644). GPR files were passed through a custom-built
quality control filter which flagged all probes that didn't
meet all of the following criteria in both the green and red
channels: (1) % > B + 2SD greater than 30; (2) median –
background > 0; (3) signal-to-noise ratio greater than 1.5.
These filtered results were then normalized using the
default parameters (plus Lowess normalization) in Agi-
lent's Chip Analytics software version 1.3. A post-normal-
ization MA plot is shown in Figure 2B. We then used a
modified version of the mixture model (reducing their
gamma+normal+gamma model to a simple gamma+nor-
mal model) described by Khalili et al [39] to classify
probes into one of two groups: bound or not bound. Fig-
ure 2C shows the fit of the gamma+normal mixture model
to our data. One benefit of this type of analysis is that we
are able to directly estimate our false positive rates based
on a probe's probability of assignment to the "unbound"
distribution.
Since each promoter contains many probes, for each pro-
moter region we chose the probe with the best p-value for
inclusion into the "bound" distribution and compared
these across the various experimental treatments and rep-
licates. We found that between replicates these "best
probes" were within 80 bases of each other (the resolution
of the array) 90% of the time. We used the following cri-
teria to classify promoters within individual experiments:
strongly bound promoters had probes that were classified
in the "bound" distribution with a p-value less than 0.05.
Weakly bound promoters were those that did not signifi-
cantly fall within the "unbound" distribution with a p-
value of 0.05. Unbound promoters were those whose
probes fell within the "unbound" distribution with a p-
value less than 0.05. As Figure 2D illustrates, by combin-
ing replicate experiments, we were able to classify each
promoter into "highly on" (both replicates were strongly
bound), "medium on" (one replicate was strongly bound,
the other weakly bound), "low on" (both replicates are
weakly bound), "weakly off" (replicates don't agree, so we
fall back on the null hypothesis of no binding), or
"strongly off" (both replicates show an unbound state).
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